PANACEA BIOTEC LTD.

Panacea Biotec Pharma Ltd., a wholly owned subsidiary of Panacea Biotec Ltd., has received a Show Cause Notice (SCN) dated July 23, 2026, from the Assistant Commissioner, Goods and Services Tax (GST), Delhi. The notice alleges a total tax liability of ₹4.06 Crore, including tax, interest, and penalty, for the Financial Year 2022-23. The alleged discrepancy pertains to an excess claim of Input Tax Credit (ITC) in the annual return filed for that period. The company is currently collating details to prepare a response and does not foresee any adverse financial or operational impact from this notice at this stage.

Panacea Biotec Ltd has filed an appeal on July 16, 2026, before the Hon'ble High Court of Punjab and Haryana, Chandigarh, against the remaining fourth award from the Industrial Tribunal, S.A.S Nagar, Mohali. This follows earlier appeals against three other awards. The company had previously informed about its intention to appeal the fourth award. The High Court has already heard the initial three appeals and issued an interim order preventing coercive steps against the company. The awards relate to issues such as setting aside transfer of workmen, wage revision, and reinstatement with back wages. Panacea Biotec believes the awards are challengeable and does not foresee any material adverse financial or operational impact.

Panacea Biotec Limited has filed a disclosure regarding an inter-se transfer of shares within the promoter group. Rajesh Jain (HUF) acquired 2,00,000 equity shares of the company from Dr. Rajesh Jain through a gift. This acquisition was made under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, for which an exemption report was submitted to SEBI on July 8, 2026. The transaction resulted in Rajesh Jain (HUF)'s shareholding increasing to 0.09% and Dr. Rajesh Jain's shareholding decreasing to 13.48%. The filing confirms compliance with relevant SEBI regulations.

Panacea Biotec Ltd has filed appeals before the Hon'ble High Court of Punjab and Haryana against three out of four Awards received from the Industrial Tribunal, S.A.S. Nagar, Mohali. These Awards, dated March 19, 2026, and received on April 9, 2026, relate to the transfer and reinstatement of 23 workmen, granting relief including full back wages and wage revision. The company is also in the process of appealing the fourth Award. Panacea Biotec believes these Awards are challengeable and does not foresee any material adverse financial or operational impact.

Panacea Biotec Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The window will be shut from July 01, 2026, until 48 hours after the announcement of the unaudited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, to prevent potential insider trading activities. The company will inform the stock exchanges in due course about the date of the Board of Directors' meeting to approve these financial results.

Panacea Biotec Limited has filed a disclosure regarding an inter-se transfer of 2,00,000 equity shares by way of gift. Dr. Rajesh Jain transferred these shares to Rajesh Jain (HUF), a promoter group member. This transaction falls under Regulation 10(1)(a)(ii) of SEBI SAST Regulations, exempting it from an open offer. The transfer was at NIL price, reflecting a gift between related promoter entities. Post-transaction, Rajesh Jain (HUF) holds 0.09% of the diluted share capital, while Dr. Rajesh Jain's holding slightly decreased.

Panacea Biotec has launched the DENSTAR project, a four-year initiative aimed at advancing the licensure of its dengue vaccine, DengiAll®, in sub-Saharan Africa (sSA) and facilitating its global use. Funded by the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), the project aligns with the EDCTP3 mission to combat Neglected Tropical Diseases. The DENSTAR consortium, comprising 10 partners from 9 countries, will conduct Phase I/III studies in Africa to confirm the vaccine's safety and efficacy. This public-private partnership seeks to reduce the dengue disease burden and ensure equitable access to prevention tools, with DengiAll® offering advantages like single-dose and cost-efficiency for widespread deployment.

Rajesh Jain (HUF), a member of the Promoter's Group of Panacea Biotec Limited, is acquiring 2,00,000 equity shares through an off-market inter-se transfer by way of gift from Dr. Rajesh Jain, a Promoter. This transaction falls under Regulation 10(1)(a)(ii) of SEBI (SAST) Regulations, 2011, exempting it from an open offer. The acquisition is at NIL price. Post-acquisition, Rajesh Jain (HUF)'s shareholding will be 13.48% of the total paid-up share capital.

Panacea Biotec Ltd. has reported the details of shares dematerialised during May 2026, as per SEBI regulations. A total of 61,105,526 shares were dematerialised by May 31, 2026, comprising 53,904,650 shares through NSDL and 7,200,876 shares through CDSL. The company has provided a certificate from its RTA, Skyline Financial Services Pvt. Ltd., confirming these figures. This filing is a routine regulatory update regarding the conversion of physical shares to dematerialised form.

Panacea Biotec Ltd's Board of Directors approved the appointment of Mr. Rajinder Singh Manku as an additional non-executive independent director, effective July 1, 2026, for a 5-year term, subject to shareholder approval. The board also approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. The company passed over dividend payments for FY26 due to losses. Total income from operations for the year ended March 31, 2026, was ₹41,349 Lakh, with a net loss of ₹2,988 Lakh after tax.